Healthcare | January 05, 2023
Viatris acquires Oyster Point Pharma and Famy Life Sciences
Acquisitions have the potential to add at least $1 billion in sales by 2028
Acquisitions have the potential to add at least $1 billion in sales by 2028
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
MVUs will provide diagnosis treatment, vaccination, artificial insemination, minor surgical interventions, audio-visual aids and extension services to farmers/animal owners at their doorstep in far flung areas.
The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.
Subscribe To Our Newsletter & Stay Updated
